Jpmorgan Chase & CO Adc Therapeutics Sa Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ADCT
# of Institutions
78Shares Held
52.8MCall Options Held
300KPut Options Held
59.3K-
Redmile Group, LLC San Francisco, CA15.3MShares$46.1 Million3.15% of portfolio
-
Prosight Management, LP Dallas, TX9.57MShares$28.9 Million9.45% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.32MShares$13 Million0.33% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$10.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.97MShares$8.95 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $234M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...